Bio Roundup: Trump’s Rx Silence, PCSK9 News, Amgen’s Migraines & More
Xconomy
NOVEMBER 18, 2016
Speculation swirled this week around the incoming U.S. president’s intent to make good on his angry campaign rhetoric on drug prices, while the Associated Press reported that naming-and-shaming—that is, Congress hauling executives into hearings and penning angry letters—certainly hasn’t done the trick.
40 
Let's personalize your content